Health Canada approves Eli Lilly’s GLP-1 pill for weight loss

Advertisement

Advertise with us

TORONTO - Health Canada has authorized a new GLP-1 medication for weight loss that is a pill taken every day, rather than weekly injections.  

Read this article for free:


By clicking the button above, an account will be created and you will begin to receive some of our recommended newsletters. You may opt out of any newsletter by visiting your Email and Communication Preferences page or by clicking "unsubscribe" at the bottom of any email.

or

Already have an account? Log in here »

We need your support!
Local journalism needs your support!

As we navigate through unprecedented times, our journalists are working harder than ever to bring you the latest local updates to keep you safe and informed.

Now, more than ever, we need your support.

Starting at $15.99 plus taxes every four weeks you can access your Brandon Sun online and full access to all content as it appears on our website.

Subscribe Now

or call circulation directly at (204) 727-0527.

Your pledge helps to ensure we provide the news that matters most to your community!

To continue reading, please subscribe:

Add Brandon Sun access to your Free Press subscription for only an additional

$1 for the first 4 weeks*

  • Enjoy unlimited reading on brandonsun.com
  • Read the Brandon Sun E-Edition, our digital replica newspaper
Start now

*Your next Free Press subscription payment will increase by $1.00 and you will be charged $20.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.

TORONTO – Health Canada has authorized a new GLP-1 medication for weight loss that is a pill taken every day, rather than weekly injections.  

Eli Lilly’s Foundayo is approved for adults with obesity as well as those who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea.

In addition to promoting and maintaining weight loss, the pill is also approved to help treat Type 2 diabetes. 

A ropa vieja dish from Cuba Libre Restaurant and Rum Bar's GLP-Wonderful menu is prepared for serving at the restaurant in Philadelphia, on Friday, March 6, 2026. (AP Photo/Mingson Lau)
A ropa vieja dish from Cuba Libre Restaurant and Rum Bar's GLP-Wonderful menu is prepared for serving at the restaurant in Philadelphia, on Friday, March 6, 2026. (AP Photo/Mingson Lau)

Eli Lilly also makes the injectable drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. Tirzepatide acts on two receptors associated with insulin production and hunger: GLP-1 and GIP. 

Competitor Novo Nordisk manufactures injectables Ozempic and Wegovy, which contain the active ingredient semaglutide. Semaglutide acts on GLP-1 receptors. Several other companies make generic semaglutide sold in Canada. 

The class of drugs known as GLP-1s have revolutionized weight-loss treatment and experts say some patients may prefer to take a pill rather than an injection. 

There is another GLP-1 pill — Novo Nordisk’s Rybelsus — already on the market in Canada, but it is only approved for Type 2 diabetes management and not for weight loss.  

The active ingredient in Foundayo is orforglipron, a non-peptide GLP-1 receptor agonist.

Because it’s a smaller molecule than peptides semaglutide and tirzepatide, orforglipron can be taken orally and absorbed without being broken down by the digestive system, said Dr. Ehud Ur, an endocrinologist in Vancouver who is not associated with either Eli Lilly or Novo Nordisk. 

“It seems to be just as good as if not better” for weight loss as semaglutide and tirzepatide, he said.

The most common side effects of GLP-1 medications — both injectable and oral — include gastrointestinal issues, such as nausea or vomiting. 

Ur said whether he would prescribe Foundayo depends on the patient, partly because he is still waiting for clinical trial results on whether or not orforglipron has a cardiovascular benefit like semaglutide and tirzepatide do. 

Foundayo received Health Canada authorization on Nov. 13. Eli Lilly spokesperson Ethan Pigott said the company expects the pills to be available in pharmacies in January. 

There may soon be a second GLP-1 weight-loss pill option in Canada: competitor Novo Nordisk’s Wegovy pill, which is still awaiting Health Canada approval. 

Both Foundayo and the Wegovy pill are approved and available in the U.S. 

Even though Wegovy is made of the large peptide molecule semaglutide, Novo Nordisk is able to manufacture it in pill form by adding an ingredient called salcaprozate sodium to protect it from being broken down by digestive enzymes. 

Once the pill is swallowed, salcaprozate sodium, or SNAC, temporarily makes the area around it less acidic and helps it pass through the stomach lining into the bloodstream, Novo Nordisk spokesperson Kate Hanna said in an email on Wednesday.  

GLP-1 medications should be used in conjunction with diet and exercise for weight loss, experts say.   

 This report by The Canadian Press was first published Nov. 18, 2026.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

Report Error Submit a Tip

Lifestyles

LOAD LIFESTYLES ARTICLES